Ligand Pharmaceuticals (LGNDZ) EPS (Weighted Average and Diluted) (2016 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with $2.18 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 229.76% to $2.18 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.89 through Dec 2025, up 3045.0% year-over-year, with the annual reading at $6.13 for FY2025, 2886.36% up from the prior year.
- EPS (Weighted Average and Diluted) hit $2.18 in Q4 2025 for Ligand Pharmaceuticals, down from $5.68 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $5.68 in Q3 2025 to a low of -$2.88 in Q2 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.64 across 5 years, with a median of $0.4 in 2022.
- Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 2315.38% in 2024 and later skyrocketed 1556.41% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.19 in 2021, then crashed by 352.63% to -$0.86 in 2022, then skyrocketed by 209.3% to $0.94 in 2023, then tumbled by 278.72% to -$1.68 in 2024, then soared by 229.76% to $2.18 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for LGNDZ at $2.18 in Q4 2025, $5.68 in Q3 2025, and $0.24 in Q2 2025.